1. Home
  2. Browse
  3. National Institutes of Health
  4. PAR-25-266

PAR-25-266National Institutes of HealthR21

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

Deadline
Award ceiling
$200,000
Awards
Not stated
Posted
Dec 2, 2024

Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.

Or read the full text and all 3 review criteria here, free with an account. Create free account

Summary

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate…

Related NIH announcements6

Companion announcements with the same title first, then other open R21 announcements on related subjects with at least two weeks to go.

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)

PAR-25-265National Institutes of Health3 review criteria on file

—

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

PAR-25-143National Institutes of Health3 review criteria on file

—

Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)

PAR-25-291National Institutes of Health3 review criteria on file

$200k

Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)

PAR-25-286National Institutes of Health3 review criteria on file

—

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)

PAR-25-044National Institutes of Health3 review criteria on file

—

Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)

PAR-25-256National Institutes of Health3 review criteria on file

—

The full announcement, free with an account

  • The full announcement text, not just the first two sentences
  • All 3 review criteria reviewers score this against, extracted from this announcement

On Plus, $39 a month

  • The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
  • Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
  • A Reviewer Scorecard of your draft against these criteria
Create free accountSign in

No card required. Browsing is free.

More from National Institutes of Health

Open now with at least two weeks to apply, soonest deadline first.

NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-057National Institutes of Health6 review criteria on file

—

Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)

RFA-DK-27-108National Institutes of Health3 review criteria on fileagency framework

$500k

Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

RFA-DK-27-139National Institutes of Health

—

Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)

RFA-DK-27-112National Institutes of Health

—

Everything open from National Institutes of Health

Source record: https://grants.nih.gov/grants/guide/pa-files/PAR-25-266.htmlVia the NIH Guide. Last checked against the source . Always confirm dates with the funder.